MORAb-202

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Carcinoma, Non-Small-Cell LungNeoplasms, Ovarian

Phase 2

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

TerminatedNCT05577715

Bristol-Myers SquibbCarcinoma, Non-Small-Cell Lung

Start: 2022-11-14End: 2024-08-12Updated: 2025-09-04

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

CompletedNCT05613088

Bristol-Myers SquibbNeoplasms, Ovarian

Start: 2023-02-01End: 2025-09-10Updated: 2026-04-30